Kazia Therapeutics-Spon ADRKZIA
13F holders, Q2 2025 (June 30)10holders
$6.27avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Kazia Therapeutics-Spon ADR (KZIA) in their 13F filings. The largest holders were Dauntless Investment Group, LLC ($726K), Barclays PLC ($150K) and UBS Group AG ($19K).
- Company
- Kazia Therapeutics-Spon ADR
- CUSIP
- 48669G303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $726K |
| Exits | 0 | $0 |
Ownership 10 holders
| Dauntless Investment Group, LLC | 3.41% | New | 115,769 | $726K |
| Barclays PLC | 0.00% | No change | 24,000 | $150K |
| UBS Group AG | 0.00% | Reduce -42.4% | 3,029 | $19K |
| Rhumbline Advisers | 0.00% | Add +54.6% | 591 | $4K |
| GAMMA Investing LLC | 0.00% | Reduce -0.1% | 265 | $2K |
| Arax Advisory Partners | 0.00% | No change | 200 | $1K |
| SBI Securities Co., Ltd. | 0.00% | New | 100 | $627 |
| MAI Capital Management | 0.00% | Reduce -93.3% | 52 | $327 |
| Osaic Holdings, Inc. | 0.00% | No change | 10 | $62 |
| Allworth Financial LP | 0.00% | Add +400.0% | 1 | $7 |
"% of holder's portfolio" is KZIA's weight in each manager's 13F, not the share of Kazia Therapeutics-Spon ADR the manager owns.